Skip to content

Own Cartilage Cells Transplantation: validation of the therapy protocol for Cartilage Lesions

Autologous Chondrocyte Transplantation: validation of the therapy protocol for Joint Cartilage Lesions

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6fgy76
Enrollment
Unknown
Registered
2019-06-05
Start date
2017-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Articular pain/knee

Interventions

There will only be one group with 3 participants. All participants will be submitted to a single intervention: there will be surgery to implant a porcine collagen membrane inside the knee containing c
Procedure/surgery
A11.329.171

Sponsors

Hospital Israelita Albert Einstein
Lead Sponsor
Hospital Israelita Albert Einstein
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Male; age between 18 and 40 years; with or without anterior cruciate ligament (ACL) injury; lesion of the articular cartilage in the femur or patella; degrees 2 or 3 of the International Cartilage Repair Society (ICRS) classification; diameter greater than 2 cm; symptomatic; without improvement with conservative treatment based on physical therapy, weight loss and medications

Exclusion criteria

Exclusion criteria: Superficial chondral lesion (classification ICRS grade 1); Subchondral bone lesion (ICRS grade 4); Osteoarthritis (Kellgren-Lawrence rating greater than 1); Misalignment of the mechanical axis of the lower limb in the frontal plane; Multiple ligament lesions; Previous surgeries in the affected knee; Meniscal lesions not sutured; Systemic inflammatory diseases; Inability to adhere to the rehabilitation protocol; Functional limitations due to pain in the spine or hips; Claustrophobia; Metal implants that ensure the performance of magnetic resonance; Obesity (BMI greater than 30); Smoking; Gestation; Cognitive changes with inability to read, understand and sign the EHIC.

Design outcomes

Primary

MeasureTime frame
To assess the safety of the procedure by the method of observation of the incidence and severity of complications according to version 4.0 of the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events). We will observe the absence of serious adverse events in the period one year

Secondary

MeasureTime frame
To evaluate the efficacy of the surgery by measuring the WOMAC scales validated for the Portuguese language, IKDC validated for the Portuguese language and MOCART, from the observation of a variation of at least 10 points for less than WOMAC and 10 points for more of the IKDC and MOCART, in the mean of the scales in the pre- and post-intervention measurements

Countries

Brazil

Contacts

Public ContactAlessandro;Mario Zorzi;Ferretti

Hospital Israelita Albert Einstein;Hospital Israelita Albert Einstein

arzorzi@einstein.br;mario.ferretti@einstein.br(11)2151-1233;+55-011-21511233

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 18, 2026